Are We Using Slow-Acting Symptomatic Chondroprotective Drugs Conscious Enough?

Area of Science:

• Orthopedics and Sports Medicine
• Pharmacology
• Regenerative Medicine

Background:

• Osteochondral injuries are common across all age groups, impacting joint function and quality of life.
• Current treatments focus on pain relief and restoring joint mobility.
• Many chondroprotective agents, classified as nutritional supplements, lack rigorous clinical evaluation and regulatory oversight.

Purpose of the Study:

• To highlight the importance of understanding clinical adverse effect profiles of widely prescribed chondroprotective drugs.
• To examine the pharmacological mechanisms of action and applications of these unregulated drug combinations.
• To emphasize the need for controlled studies on chondroprotective agents.

Main Methods:

• A comprehensive literature search of electronic databases was conducted for chondroprotective drugs.
• Initial screening identified 1502 potentially relevant studies.
• 225 full-text articles were evaluated, with no controlled, blinded, randomized, or comparative studies meeting the inclusion criteria.

Main Results:

• Prescribing chondroprotective drugs containing glucosamine (GS) and chondroitin sulfate (CS) necessitates consideration of patient comorbidities, such as glucose intolerance.
• Potential risks include mineral toxicity due to drug ingredients and complications associated with injected hyaluronan.
• No studies comparing different molecular weights of hyaluronan were found.

Conclusions:

• There is a critical need for clinical, controlled, and comparative studies to establish the efficacy of chondroprotective drugs.
• Such studies are essential to determine the actual benefits of these agents and guide optimal timing for surgical interventions.
• Further research is required to define the role of these agents in managing osteochondral injuries.